Review



targetmol bioactive compound library  (TargetMol)


Bioz Verified Symbol TargetMol is a verified supplier
Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    TargetMol targetmol bioactive compound library
    Targetmol Bioactive Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 107 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/targetmol+bioactive+library/Bioactive+Compound+Library/pm42456852-186-14-14
    Average 97 stars, based on 107 article reviews
    targetmol bioactive compound library - by Bioz Stars, 2026-11
    97/100 stars

    Images

    Related Articles

    Activity Assay:

    Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen
    Article Snippet: Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.. We then screened a subset of ~ 900 molecules from the TargetMol Bioactive Library and identified two main groups compounds.. The first group disrupted APOE4 brain endothelial cells as they were toxic or lowered TEER and many inhibited mTOR.The first group disrupted APOE4 brain endothelial cells as they were toxic or lowered TEER and many inhibited mTOR.

    Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen
    Article Snippet: Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.. APOE4 -brain endothelial cells were treated for 24 h with 1 μM of 900 + compounds selected from the TargetMol Bioactive Library.. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots).A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots).

    Disruption:

    Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen
    Article Snippet: Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.. We then screened a subset of ~ 900 molecules from the TargetMol Bioactive Library and identified two main groups compounds.. The first group disrupted APOE4 brain endothelial cells as they were toxic or lowered TEER and many inhibited mTOR.The first group disrupted APOE4 brain endothelial cells as they were toxic or lowered TEER and many inhibited mTOR.

    Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen
    Article Snippet: Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.. APOE4 -brain endothelial cells were treated for 24 h with 1 μM of 900 + compounds selected from the TargetMol Bioactive Library.. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots).A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots).

    Concentration Assay:

    Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen
    Article Snippet: Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.. We then screened a subset of ~ 900 molecules from the TargetMol Bioactive Library and identified two main groups compounds.. The first group disrupted APOE4 brain endothelial cells as they were toxic or lowered TEER and many inhibited mTOR.The first group disrupted APOE4 brain endothelial cells as they were toxic or lowered TEER and many inhibited mTOR.

    Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen
    Article Snippet: Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.. APOE4 -brain endothelial cells were treated for 24 h with 1 μM of 900 + compounds selected from the TargetMol Bioactive Library.. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots).A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots).

    Control:

    Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen
    Article Snippet: Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.. We then screened a subset of ~ 900 molecules from the TargetMol Bioactive Library and identified two main groups compounds.. The first group disrupted APOE4 brain endothelial cells as they were toxic or lowered TEER and many inhibited mTOR.The first group disrupted APOE4 brain endothelial cells as they were toxic or lowered TEER and many inhibited mTOR.

    Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen
    Article Snippet: Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.. APOE4 -brain endothelial cells were treated for 24 h with 1 μM of 900 + compounds selected from the TargetMol Bioactive Library.. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots).A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots).

    Analysis:

    Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen
    Article Snippet: Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.Our final protocol met the reproducibility acceptance criteria for a statistically validated assay.. We then screened a subset of ~ 900 molecules from the TargetMol Bioactive Library and identified two main groups compounds.. The first group disrupted APOE4 brain endothelial cells as they were toxic or lowered TEER and many inhibited mTOR.The first group disrupted APOE4 brain endothelial cells as they were toxic or lowered TEER and many inhibited mTOR.

    Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen
    Article Snippet: Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.Fig. 5 Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells.. APOE4 -brain endothelial cells were treated for 24 h with 1 μM of 900 + compounds selected from the TargetMol Bioactive Library.. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots).A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots).



    Similar Products

    97
    TargetMol targetmol bioactive compound library
    Targetmol Bioactive Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/targetmol+bioactive+library/Bioactive+Compound+Library/pm42456852-186-14-14
    Average 97 stars, based on 1 article reviews
    targetmol bioactive compound library - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    94
    TargetMol targetmol l9500 bioactive library
    Targetmol L9500 Bioactive Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/targetmol+bioactive+library/Target-Focused+Phenotypic+Screening+Library/pm42349121-33-6-6
    Average 94 stars, based on 1 article reviews
    targetmol l9500 bioactive library - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    TargetMol targetmol bioactive compounds library
    Targetmol Bioactive Compounds Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/targetmol+bioactive+library/Bioactive+Compounds+Library+Max/pm41729167-42-14-18
    Average 94 stars, based on 1 article reviews
    targetmol bioactive compounds library - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    97
    TargetMol targetmol l4000 library
    Targetmol L4000 Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/targetmol+bioactive+library/Bioactive+Compound+Library/10__1021_slash_jacsau__5c01622-40-26-26
    Average 97 stars, based on 1 article reviews
    targetmol l4000 library - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    97
    TargetMol targetmol bioactive library
    Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol <t>Bioactive</t> Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2
    Targetmol Bioactive Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/targetmol+bioactive+library/Bioactive+Compound+Library/pmc12964606-44-11-11
    Average 97 stars, based on 1 article reviews
    targetmol bioactive library - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    Image Search Results


    Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol Bioactive Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2

    Journal: Alzheimer's Research & Therapy

    Article Title: Proof-of-concept study: APOE4 brain endothelial cells as a phenotypic compound screen

    doi: 10.1186/s13195-026-01960-6

    Figure Lengend Snippet: Compound treatment phase, mTOR inhibitors disrupt baseline TEER of APOE4 -brain endothelial cells. APOE4 -brain endothelial cells were treated for 24 h with 1 µM of 900 + compounds selected from the TargetMol Bioactive Library. A Capacitance was > 4nF for 11 compounds, 4 of which inhibit cell cycle pathways (CDK, purple dots) and 3 PI3K/Akt/mTOR (blue dots). B , C Relative change and percentage activity of compounds. We identified compounds that either increased (light green dots, 5 compounds) or decreased (brown dots, 34 compounds) baseline TEER. 22 were inhibitors of mTOR/PI3K (blue dots) including rapamycin (arrow). E - I The ability of mTOR activators (NV-5138, L-leucine, 3BDO, MHY1485) to modulate LPS-induced TEER disruption was evaluated. E , G Compound treatment phase. E. High concentrations of mTOR activators were either toxic (2 mM L-leucine; 200 µM 3BDO) or F. disrupted TEER (100 µM 3BDO). H , I LPS Phase. High concentrations of NV-5138 (10 µM) mitigated LPS-induced TEER disruption. Data analyzed by one-Way ANOVA/matched Mixed-effects model (REML) followed by Dunnet’s multiple comparisons test comparing a compound concentration to the control group. In the compound treatment phase ( F ), * p < 0.05 for a given compound concentration compared to vehicle. In the LPS treatment phase ( H ), * p < 0.05 for a given compound concentration + LPS compared to the vehicle plus LPS group. n = 3. Upper lines indicate the concentrations different from LPS control for each compound. All statistical analysis is provided in Additional File 2

    Article Snippet: We then screened a subset of ~ 900 molecules from the TargetMol Bioactive Library and identified two main groups compounds.

    Techniques: Activity Assay, Disruption, Concentration Assay, Control, Analysis